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Abstract
Background
Malaria is a mosquito-borne, lethal disease that affects millions and kills hundreds of thousands of people each year,
mostly children. There is an increasing need for models of malaria control. In this paper, we develop a model for allocating
malaria interventions across geographic regions and time, subject to budget constraints, with the aim of minimizing the
number of person-days of malaria infection.
Methods
The model considers a range of several conditions: climatic characteristics, treatment efficacy, distribution costs, and
treatment coverage. We couple an expanded susceptible-infected-recovered (SIR) compartment model for the disease
dynamics with an integer linear programming (ILP) model for selecting the disease interventions. Our model produces
an intervention plan for all regions, identifying which combination of interventions, with which level of coverage, to use in
each region and year in a five-year planning horizon.
Results
Simulations using the model yield high-level, qualitative insights on optimal intervention policies: The optimal inter-
vention policy is different when considering a five-year time horizon than when considering only a single year, due to the
effects that interventions have on the disease transmission dynamics. The vaccine intervention is rarely selected, except
if its assumed cost is significantly lower than that predicted in the literature. Increasing the available budget causes the
number of person-days of malaria infection to decrease linearly up to a point, after which the benefit of increased budget
starts to taper. The optimal policy is highly dependent on assumptions about mosquito density, selecting different inter-
ventions for wet climates with high density than for dry climates with low density, and the interventions are found to be
less effective at controlling malaria in the wet climates when attainable intervention coverage is 60% or lower. However,
when intervention coverage of 80% is attainable, then malaria prevalence drops quickly in all geographic regions, even when
factoring in the greater expense of the higher coverage against a constant budget.
Conclusions
Our model provides a qualitative decision-making tool to weigh alternatives and guide malaria eradication efforts. We
find that a one-size-fits-all campaign is not cost-effective, and that it is better to consider geographic variations and changes
in malaria transmission over time when determining intervention strategies.
Background
Malaria remains a lethal disease affecting an estimated 200 million people and killing 627,000 in 2012 [1]. There are a variety of
interventions for treating or preventing malaria infection, but the use of these interventions is hindered by scarcity of resources.
Mathematical models provide a useful tool for evaluating intervention strategies and studying the relative effectiveness of
interventions. These evaluations will become increasingly useful as success with malaria elimination is predicted to change
transmission dynamics. In fact, the WHO Global Malaria Programme cites the specific need for operations research models to
determine the best intervention strategies in areas where transmission dynamics are changing as malaria is being eliminated
[2].
In this paper, we develop an integer linear program (ILP) and a coupled susceptible-infected-recovered (SIR) compartment
model to create a decision-making tool for planning future interventions. The model suggests the best strategy for minimizing
person-days of malaria infection over a five-year period given an initial population, cost of each intervention, and a budget
constraint. We pay special attention to the possibility of a malaria vaccine in combination with other interventions. We also
perform simulations in which we vary our budget, the efficacy of the interventions, and their cost to determine the sensitivity
of the optimal policy to these parameters.
Interventions
There are many existing methods to prevent or treat malaria infection. Our model will consider the following five interventions
and their combinations.
Long-lasting insecticidal nets (LLINs) cover sleeping individuals during the night when mosquito biting can be highest.
When intact, the nets block mosquitoes from reaching humans. The insecticides work by deterring mosquitoes from feeding
and by killing female mosquitoes that come in contact with the net. LLINs can remain effective for multiple years [3]. In
fact, the WHO Pesticide Evaluation Scheme 2005 guidelines state that LLINs should survive at least 3 years of recommended
washing and use [4].
Indoor residual spraying (IRS) is another insecticidal prevention method. IRS is believed to deter mosquitoes from
entering sprayed areas and to kill female Anopheles mosquitoes that rest on sprayed surfaces after feeding. (Resting after
feeding is a hallmark of some mosquito species while others prefer to rest outdoors [5].) Historically, IRS with an insecticide
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called dichlorodiphenyltrichloroethane was effective in reducing malaria in Europe, Asia, and Latin America. However, as
insecticide use increases, insecticide resistance has been observed in some mosquito populations in Africa, and new insecticides
must be used [1].
Intermittent preventive therapy (IPT) is the regular administration of a drug like sulfadoxine-pyrimethamnine to decrease
morbidity due to malaria in infants, children, and pregnant women. IPT decreases the chance of developing symptoms
after being bitten by an infected mosquito [6]. There is evidence that children withstand acute infection better than adults.
However, in endemic areas, adults develop acquired immunity from repeated exposures, and children remain more susceptible
to high levels of parasitemia (parasite density in the blood) [7]. Most of the 627,000 people killed by malaria in 2012 were
children in Africa, so giving IPT to infants, children, and pregnant women treats the most vulnerable population while
limiting the risk of spreading drug resistance [1].
Artemisinin combination therapy (ACT) can be used to treat a patient after they contract malaria. This is the best
treatment for uncomplicated P. falciparum malaria when confirmed by rapid diagnostic tests (RDT) [1, 8]. ACT kills the
parasites that cause symptoms and may destroy or disable the gametocytes that are responsible for infecting mosquitoes [9].
Both these factors mean that ACT increases the recovery rate.
Many malaria vaccines are in development, and one has gone through Phase III clinical trials. The complex life-cycle of
the malaria parasite makes it possible to intervene at many stages. Vaccines that target different forms of the parasite will
operate by different mechanisms, but in general, a vaccine would decrease the chance of developing symptoms and increase
the recovery rate if infected. The leading malaria vaccine candidate is the RTS,S malaria vaccine. It is an antigen composed
of the RTS and S proteins. The RTS,S vaccine is a pre-erythrocytic vaccine that presents circumsporozoite protein (CSP)
from malaria sporozoites to the immune system. CSP is a parasitic surface protein that is an important part of the invasion of
hepatocytes by sporozoites [10]. Such a vaccine will decrease the probability that a susceptible person becomes infected after
a bite from an infectious mosquito. Moreover, it is believed the vaccine could increase a person’s recovery rate by increasing
their exposure to asexual blood-stage parasites, thereby boosting their immunity [10]. (By contrast, a transmission-blocking
vaccine that acts in mosquitoes would decrease the probability of transmission from an infectious mosquito but would not
change the human recovery rate.)
Literature Review
Our work extends a single-stage optimization model of Dimitrov et al. Their model divides the country of Nigeria into
approximately 270,000 cells and chooses one action (either a single intervention or no intervention) for each cell over a year,
subject to budget constraints, to minimize societal costs caused by malaria infection. The model also identifies optimal
locations for supply distribution centers. They treat the societal benefit of each intervention as an exogenous parameter that
depends on geographic characteristics. This allows their model to consider geographic variability in malaria dynamics [11].
However, because malaria dynamics depend on the fraction of the population that is infectious, a quantity that the
interventions are themselves trying to reduce, the framework of Dimitrov et al. does not permit the examination of multiyear
efforts against malaria in which the optimal policy might vary over time as the malaria dynamics shift. This paper extends
the optimization model above to select interventions (or combinations thereof) over multiple years by explicitly incorporating
malaria disease dynamics over time in response to those interventions. This is a novel approach that combines two areas of
mathematics that do not regularly interact: integer linear programming from the area of operations research and differential
equations modeling from the area of mathematical epidemiology.
There is a long history of mathematical models of malaria transmission, going back to the work of Sir Ronald Ross in the
early 1900’s [12, 13]. In recent years, malaria has drawn significant attention from the academic community. Epidemiologists
have traditionally modeled the spread of malaria in a population using variations on the susceptible-infected-recovered (SIR)
model to capture different aspects of the disease. Mandal et al. survey the models found in the literature and offer a hierarchy
based on model complexity [13].
In order for our model to make informed choices about which interventions to distribute, we must understand how
the dynamics of disease transmission change after treatment interventions. Lindblade et al. and Killeen et al. study the
protective effect of insecticide-treated nets or long-lasting insecticidal nets [14, 15]. Bousema et al. investigate how artemisinin
combination therapy reduces the circulation time of gametocytes, thereby reducing infectiousness [16]. Garner and Graves
examine the community benefits of artemisinin combination therapy [17]. Chandramohan et al., Grobusch et al., and Aponte
et al. quantify the protective effects of intermittent preventive therapy for infants [6, 18, 19]. Pluess et al. review the effects
of indoor residual spray of insecticide [5]. These results are used to inform our choice of disease transmission parameters, as
described later under Effects of Interventions on SIR Parameters.
Our model includes in its portfolio of interventions a vaccine that is currently in development. Prosper et al. model
the interaction between vaccine- and naturally-acquired immunity using a five-compartment model. Their model augments
the S, I, and R classes with a partially-immune (due either to vaccination or natural immunity) susceptible class and a
moderately-infectious class for infected, partially-immune individuals. They find that disease burden can be decreased only if
a highly effective vaccine is coupled with a policy of actively treating asymptomatic infections in partially immune individuals
[20]. Bojang et al. report there is minimal potential effect for a malaria vaccine given to adult men, and Asante et al. study
the positive potential protective benefits of administering the vaccine to children [21, 22].
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There are extensions to the SIR framework that we do not consider here. Koella and Antia model the reduced efficacy
of interventions due to the spread of drug-resistant strains of malaria [23]. Our model does not incorporate drug-resistance,
so any policy recommended by our model should be evaluated in this context. Other researchers, for example Dawes et al.
[24] and Koudou et al. [25], focus on the mosquitoes’ malaria dynamics by analyzing the effects of interventions on mosquito
morbidity and mortality rates and the usefulness of the resulting manipulation of said rates. We do not model changing
mosquito population explicitly; instead we represent the effects of interventions on the mosquito population as changes in
the parameter values used in the human SIR model.
While the above references provide detailed models of malaria’s complex dynamics, we have chosen to develop a simple
(SIR) model that accommodates the effects of several types of interventions, while maintaining the computational tractability
required by the optimization model. In the next section, we describe our model and simulation approach in greater detail.
Methods
We consider the problem of allocating malaria treatments to many regions when limited by scarce resources. We assume
a fixed annual budget shared across several geographic regions having different initial incidences and transmission rates of
malaria and different unit costs for distributing treatment. We consider a portfolio of interventions that can be selected,
including some in combination, each having its own effects on malaria transmission. Each intervention is selected at a
particular coverage, which is the percentage of the population that receives the intervention and uses it correctly. We assume
social and economic losses are proportional to the time spent infectious, so person-days of malaria infection is our chosen
measure of the malaria burden. We seek the optimal sequence of interventions and corresponding coverage percentages for
each region and each year that minimizes the total infected person-days over a fixed time horizon.
An integer linear programming optimization model (ILP) suggests the best set of interventions in each year to minimize
person-days of malaria infection over all time steps. The ILP takes as input the number of person-days of malaria infection
that occur when a given intervention is used on a population with a given initial prevalence of malaria. The person-days of
malaria infection is estimated by a susceptible-infected-recovered (SIR) differential equations model of malaria transmission
dynamics.
Integer Linear Programming (ILP) Model
Our ILP relies on several sets, parameters, and decision variables, which we will first define.
Sets
Geographic regions: Because the cost of distributing an intervention to a particular district depends on its infrastructure and
ease of access to treatment, and the malaria transmission dynamics depend on its climate, we group districts into geographic
regions, denoted by index g. The optimization model determines the number of districts in each geographic region to receive
a particular sequence of interventions.
Population states: A population state, p, is a triplet, (S, I,R), that indicates the percentage of a district’s population
susceptible to (S), infected by (I), or recovered from and temporarily immune to (R) malaria. Each district begins a year
in a particular population state and ends in a new population state that depends on how the chosen intervention affects
the malaria disease dynamics. (The model for determining the disease progression is described in the section Differential
Equations (DE) Model.)
Actions: The set of actions is the set of possible choices of intervention (including certain combinations of interventions, or
the possibility of applying no intervention.) We refer to our choice of intervention at a determined coverage level in a district
as an action, denoted by index i.
Parameters
Ainigpq is an indicator variable whose value is 1 if action i applied to a district of geographic region g, initially in population
state p causes a transition to population state q, and 0 otherwise.
Aoutigp is an indicator variable whose value is 1 if action i applied to a district of geographic region g, initially in population
state p causes a transition to a different population state, and 0 otherwise.
Bt is the annual budget for year t; the combined cost of our actions across all districts in year t must not exceed this value.
Cig is the cost of action i in any district in geographic region g.
Ipg is the number of districts in geographic region g that are initially in population state p at the first time step.
Lipg is the number of person-days of malaria infection incurred in a district in geographic region g, initially in population
state p, under action i.
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N is a number larger than the total number of population states.
T is the time horizon, in years, considered by the model.
Decision variables
Ppgt is the number of districts in geographic region g that are initially in population state p at the start of year t.
aOUTipgt is the number of districts in geographic region g that are initially in population state p at the start of year t and are
assigned action i.
aINipqgt is the number of districts in geographic region g that are initially in population state p at the start of year t, are
assigned action i, and end in population state q.
Model
Using these sets, parameters and decision variables, we can define the following integer linear program.
min
∑
t,i,p,g
Lipga
OUT
ipgt (1)
s.t.
∑
i,g
Cig
∑
p
aOUTipgt ≤ Bt ∀t (2)
Pp,g,t=1 = Ipg ∀p, g (3)∑
p
Ppgt =
∑
p
Pp,g,t+1 ∀g, t (4)∑
i
aOUTipgt = Ppgt ∀p, g, t (5)
Ppgt +
∑
i,q
aINipqgt −
∑
i
aOUTipgt = Pp,g,t+1 ∀p, g, t (6)∑
p
aINipqgt = a
OUT
iqgt ∀i, q, g, t (7)
aINipqgt ≤ N ·Ainigpq ∀i, p, q, g, t (8)
aOUTipgt ≤ N ·Aoutigp ∀i, p, g, t (9)
Ppgt, a
IN
ipqgt, a
OUT
ipgt ≥ 0, integer ∀i, p, q, g, t
The objective function in expression (1) minimizes the cumulative person-days that each district spends in the infected
state over the time horizon, as a function of our choice of actions. Constraint (2) requires the chosen set of interventions to
be within budget in each year. Constraint (3) initializes the population variable at the start of the time horizon. Constraints
(4)—(7) are bookkeeping constraints that keep track of the number of districts in each geographic region and population
state as a function of the actions chosen. Constraints (8) and (9) assure that districts transition out of population state p to
population state q only when an appropriate action has been taken. The last constraint requires all decision variables to be
nonnegative integers.
Differential Equations (DE) Model
Several of the parameters used by the ILP model, specifically Ainigpq, A
out
igp and Lipg depend on the dynamics of malaria
progression. The susceptible-infected-recovered (SIR) model is a standard system of nonlinear ordinary differential equations
for analyzing the transmission of malaria [13, 23]. We modify the standard model and use a coupled six-class compartment
model with separate SIR compartments for treated and untreated individuals. This coupling of treated and untreated SIR
classes allows us to model population-wide benefits caused by decreased infectiousness of a treated subpopulation. For an
initial population state and action, we solve this system of equations to determine the population state after one year. This
gives us the indicator parameters Ainigpq and A
out
igp . We also use the solution to this system of differential equations to estimate
the burden of malaria, measured in infected person-days, during that year. For each district in geographic region g, beginning
the year in a particular population state p, having been assigned action i, we numerically integrate the infected class curve
that results under those conditions, multiplied by the district’s population. This estimates the number of people who are
infected over the year times the number of days for which they remain infected. This number is then input into the linear
programming model as the value of Lipg. This is pre-solved for all possible population states and actions, and the results are
stored as input data for the ILP.
We now define the parameters, state variables and system of differential equations.
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Parameters
au (at) is the number of bites per mosquito per untreated (respectively, treated) human per day.
bu (bt) is the transmission efficacy from infected mosquito to susceptible, untreated (resp., treated) human.
c is the transmission efficacy from infected human to susceptible mosquito.
δ is the daily birth rate and death rate. We assume constant population.
γu (γt) is the recovery rate for untreated (resp., treated) people. Its reciprocal is the average time that a person is infected
with malaria.
hu (ht) is the force of infection, that is, the rate at which untreated (resp., treated) susceptible humans become infected with
malaria.
mu (mt) is the number of mosquitoes per untreated (resp., treated) human.
µ is the mosquito mortality rate.
ω is the duration of immunity without reinfection.
q is the treatment coverage, the percentage of the population that receives a treatment and uses it correctly. We assume the
same percentage of newborns are born into the susceptible, treated class. The remaining fraction, 1 − q, are born into the
susceptible, untreated class.
ρu (ρt) is rate of immunity loss for recovered untreated (resp., treated) humans.
τ is the incubation period of malaria in the mosquito.
State Variables
Su (St) is the proportion of the population that is susceptible and untreated (resp., treated).
Iu (It) is the proportion of the population that is symptomatic, infectious, and untreated (resp., treated).
Ru (Rt) is the proportion of the population that is recovered with acquired immunity and untreated (resp., treated).
Model
The proportions of the population belonging to each of the six classes can be determined by solving the following system of
differential equations:
dSu
dt
= δ(1− q)− (δ + hu)Su + ρuRu (10)
dIu
dt
= huSu − (δ + γu)Iu (11)
dRu
dt
= γuIu − (δ + ρu)Ru (12)
dSt
dt
= δq − (δ + ht)St + ρtRt (13)
dIt
dt
= htSt − (δ + γt)It (14)
dRt
dt
= γtIt − (δ + ρt)Rt. (15)
Although on the surface, the equations for the untreated population and the equations for the treated population do not
appear to be coupled, the coupling occurs with the parameters hu and ht, which are the force of infection parameters. They
have been derived by Smith and McKenzie [26] to be:
hu =
mua
2
ubuce
−µτ (Iu + It)
µ+ auc(Iu + It)
(16)
ht =
mta
2
t btce
−µτ (Iu + It)
µ+ atc(Iu + It)
. (17)
We see these rates are functions of the total proportion of infectious people, Iu + It, which couples the system of differential
equations. The more infectious people there are in either the untreated or treated group, the faster the rate at which
susceptible people in either group can become infected.
The rates of immunity loss, ρu and ρt, are functions of hu and ht, respectively and further couple the system. The
procedure for deriving the rate of immunity loss has been shown by Aron and May [27]. These equations assume that being
exposed to malaria while recovering resets the duration of immunity.
ρu =
hu + δ
eω(hu+δ) − 1 (18)
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ρt =
ht + δ
eω(ht+δ) − 1 (19)
This is a general model that does not consider the effect an intervention can have on the transmission of the disease. In
the specific case of ACT, a medication that clears infection rapidly, the length of time a malaria patient is carrying infectious
gametocytes in her blood is significantly reduced [16, 28]. Because of this, we make the assumption that ACT clears parasites
before the body has time to develop acquired immunity; therefore, we assume infected people treated with ACT skip the
recovered class and transition directly back to the susceptible class. To reflect this, we introduce the indicator variable ψact,
which equals 1 when ACT is chosen (either alone or in combination with another intervention), and 0 otherwise. The state
equations for the untreated class are unchanged, and the equations for the treated classes become:
dSt
dt
= δq − (δ + ht)St + ρtRt + ψactγtIt (20)
dIt
dt
= htSt − (δ + γt)It (21)
dRt
dt
= (1− ψact)γtIt − (δ + ρt)Rt (22)
We see that when ACT is used, infectious individuals bypass the recovered class and transition directly to the susceptible
class.
Because we are selecting a new portfolio of interventions to distribute each year, we assume the effects of treatment last
for one year, exactly. Some of the treatments are known to last longer; for instance, the insecticide coating on mosquito nets
is believed to be effective for three years, and vaccines in development currently have an efficacy of three years. However,
assuming a duration of only one year is conservative: under this assumption, our model will underestimate the efficacy of
our interventions, and the results we would expect to see in the field should be better. Under this assumption, at the end
of each year, the six-state population (Su, Iu, Ru, St, It, Rt) can be collapsed into a more compact three-state representation:
(Su + St, Iu + It, Ru +Rt).
Coverage
The coverage, q, refers to the percentage of the population that receives a treatment and uses it correctly. For example, if
at the start of the year, the percentages of the population who are susceptible, infected and recovered are given by (S, I,R),
respectively, then the initial values of Su, Iu, Ru, St, It, and Rt for the differential equations model will be (1 − q)S, (1 −
q)I, (1− q)R, qS, qI, and qR, respectively.
However, some interventions, such as IPT and vaccine, are assumed to be distributed only to newborns and children
under the age of four. In these cases, the coverage, q, applies only to births and to the fraction of the population under the
age of four. If x is the fraction of the population under the age of four, and (S, I,R) is the initial distribution of susceptible,
infected and recovered individuals in the population, then the initial values of Su, Iu, Ru, St, It, and Rt for the differential
equations model will be (1− qx)S, (1− qx)I, (1− qx)R, qxS, qxI, and qxR.
Data
Our model relies on parameters governing intervention costs, malaria transmission, and intervention efficacy. When available,
we estimate parameter values based on malaria research literature. When using country-specific information, we use data
from Kenya or its neighbors as it is more readily available and allows us to be consistent across parameters. We also conduct
sensitivity analysis to understand how the model’s results would change under a range of scenarios concerning distribution
costs, climate and intervention efficacy. In this section, we first describe the costs of the interventions, then we describe the
baseline parameter values used in the SIR model, and we outline the changes in these parameter values under interventions
and sensitivity analysis scenarios.
Base Costs of Interventions
Our model parameter Cig is the per person, per year cost of action i in any district in geographic region g. The cost of an
action depends on the purchase price as well as transportation and distribution costs, which we assume are regional. For
the base cost, we used data provided by White et al., who survey cost and cost-effectiveness data for LLIN, IRS, IPT, and
ACT from all available sources and adjust it to 2009 USD [29]. We focused specifically on data from Kenya, except where
noted that no Kenya-specific data was available; in these cases, we used cost estimates from nearby Ethiopia, Tanzania and
Zimbabwe.
First, we list the base cost for each intervention, and in the subsequent section, we will describe how we modify those
costs to reflect transportation and distribution costs in different geographic regions. These are summarized in Table 1.
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LLIN: The average cost of a single insecticide-treated mosquito net is 7.21 USD [29], and the WHO Pesticide Evaluation
Scheme 2005 guidelines estimate a three year life span with recommended use [4]. Because our model assumes all actions
expire at the end of one year, we use an annual cost per net of 2.40 USD, which is one-third the base cost of the net.
Moreover, bed-sharing is a common practice that further reduces the per-person cost of each distributed net. The World
Health Organization recommends the assumption that an LLIN will protect 1.8 people on average [30], making the annual
per-person cost 1.33 USD.
IRS: Our IRS cost estimate assumes two rounds of household spraying with lambdacyhalothrin per person per year, at an
annual cost of 2.22 USD [29].
IPT: White et al. summarize cost estimates for distributing IPT to newborns, children and pregnant women. The mean cost
of distributing six bi-monthly doses of sulfadoxine-pyrimethamine to infants in Tanzania is reported to be 0.78 USD, and
three doses per year to children in Kenya is 1.25 USD [29]. As roughly 25% of children under the age of 4 are infants, we can
estimate a weighted average annual cost for IPT of 1.13 USD.
ACT: White et al. report malaria diagnosis and treatment costs for a variety of diagnostic methods and treatment types in
several countries. For consistency, we used costs associated specifically with rapid diagnostic tests (RDT) used in conjunction
with ACT treatment in the countries of Tanzania and Zambia. These ranged from 3.63 USD to 6.72 USD, with an average
of 4.82 USD per person treated [29]. Unlike interventions such as long-lasting insecticidal nets, which are assumed to be
distributed to the entire treated class, ACT is distributed only to members of the treated class who experience a malaria
infection. Therefore, our SIR model must estimate the number of new malaria infections per year to determine the annual
cost of ACT. According to equation (21), new infections occur with rate htSt =
dIt
dt + (δ + γt)It. Note that
dIt
dt can be
approximated by It(d+)−It(d) for small . If we discretize the year over which the treatment is available into 365 days and
let  = 1 day, we find that the number of new infections appearing on day d should be roughly It(d)− (1− (δ+ γt))It(d− 1)
times the total population. Summing this value over all days d should give an approximation of the number of new infections
incurred during the year, and hence, the number of people who received ACT.
Vaccine: Cost data for the RTS,S vaccine is not yet available since the vaccine is not yet on the market. Seo et al. use an
estimate of 7 USD per dose for the vaccine after looking at recent introductory vaccine prices ranging from 1 to 15 USD [31].
They also propose using 0.37 USD administration cost per vaccination based on the price for other vaccines used in Malawi
in the Expanded Program on Immunization (EPI). Because the RTS,S vaccine is administered in three doses, they estimate
the total cost of the vaccine at 22.11 USD per person per year [31]. Adjusting their 2012 costs to 2009 values for consistency,
we arrive at a cost of 20.66 USD per treated person per year [32].
Baseline SIR Model Parameter Values
We now describe the baseline parameter values used in the SIR model and discuss how the interventions and modeling
assumptions affect those values in the next section. This information is summarized in Table 2.
• au is the number of bites per mosquito per untreated human per day, which is estimated to be 0.25 [33].
• bu is the transmission probability from infected mosquito to susceptible, untreated human, which is estimated to be
0.022 [33].
• c is the transmission probability from infected human to susceptible mosquito, which is estimated to be 0.36 [33].
• δ is the daily birth rate and death rate. In Kenya in 2014, the estimated annual birth rate was 0.02827 births per person,
and the estimated annual death rate was 0.007 deaths per person [34]. Because we assume a constant population in our
model, we use the average of these, or 0.017635 births (deaths) per person per year, and convert it using compounding
to a daily birth (death) rate of δ = 4.7895× 10−5.
• γu is the recovery rate for untreated people. Filipe et al. estimate the average infectious period for untreated people
to be 180 days, making γu =
1
180 [35].
• mu is the mosquito density (number of mosquitoes per untreated human), which is estimated to be 20 [13].
• µ is the mosquito mortality rate, estimated to be 0.095 days−1 [35, 36].
• ω is the duration of immunity without reinfection. We use the value ω = 274 days, based on an estimate that immunity
lasts between six and twelve months [37].
• q is the treatment coverage, the percentage of the population that receives a treatment and uses it correctly. We
consider three levels of treatment coverage for each intervention, high (60%), medium (40%), or low (20%).
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• τ is the incubation period in the mosquito, estimated to be 10 days [36].
• x is the fraction of the population that is age four years or younger, which was approximately 14.6% in Kenya in 2014
[34].
To determine the force of infection (hu and ht) and the recovery rate (ρu and ρt), we use the expressions given in equations
(16) – (19).
Note that the malaria transmission parameters, au, bu, c, and mu, are very location-specific (see [36], p. 409). Adapting
this model to any location would require re-estimating these parameters.
Effects of Interventions on SIR Parameters
Each intervention, or combination of interventions, is modeled as affecting a subset of the above parameters.
LLINs protect individual users by decreasing the biting rate, at, and by killing mosquitoes that contact the insecticidal nets,
thus decreasing mt. We estimate the values of at and mt as follows:
• Let β be the proportion of mosquito exposure that occurs during sleeping hours.
• Let χLLIN be the probability of mortality for a mosquito exposed to a treated net.
• As before, let mu be the baseline mosquito density absent any treatment.
Then Killeen et al. [15] derive the value of at for people using LLIN as
at = au(1− β), (23)
and the value of mt for people using LLIN as
mt = mu(1− βχLLIN ). (24)
Although Figure 5 in reference [15] shows a slight increase in overall protection for the treated class as a function of q,
this increase is modest in the range of q that we consider, and so we assume that mt is independent of q. Additionally,
Killeen et al. suggest that as treatment coverage increases in a population, even non-users of LLINs benefit from decreased
mosquito density. However, we were unable to find empirical data to support a robust model of mosquito density in the
untreated population as a function of treatment coverage; therefore, we assume the untreated population experiences the
baseline mosquito density, mu, for all values of q.
To determine the new biting rate, at, and the new mosquito density, mt, for the treated classes, we use Equations (23)
and (24), respectively, with β = 0.8 [15] and χLLIN = 0.8 [14], and with au = 0.25, and mu = 20 as given earlier.
IRS decreases the number of mosquitoes per treated human, mt, in a similar manner as LLINs. Moreover, IRS can also
decrease the mosquito density in untreated areas close to treated areas; thus, mu is also affected by IRS [38]. We let χIRSt
be the reduction in mosquito density in a house treated with IRS, and we let χIRSu be the reduction in mosquito density in
an untreated house when the treatment coverage is 100% in a nearby area. Then the value of mt for a house treated with
IRS is
mt = mu(1− χIRSt) (25)
The value of mu when IRS is used at coverage q is estimated (based on the empirical results of Zhou et al. [38]) to be
muIRS = mu(1− qχIRSu). (26)
As [38] report that the mosquito density in treated areas decreases by 95%, and the mosquito density in untreated areas
decreases by 50% when the coverage in nearby treated areas is 100%, we use χIRSt = 0.95 and χIRSu = 0.5, mu = 20 as
given earlier, and q equal to the coverage associated with the selected action.
IPT decreases the probability, bt, that a susceptible person becomes infected after a bite from an infectious mosquito. We
were unable to find an estimate in the literature for the amount by which the transmission efficacy, bt, decreases when a
person is using intermittent preventative treatment. However, data from several studies reported by Aponte et al. indicate
that the protective efficacy against malaria in infants of one year of IPT is roughly 30% [6]. As this should roughly correspond
to the percentage decrease in new malaria infections observed in the SIR model output, we calibrated the model by solving
the system of differential equations for a range of values for bt and selecting the value of bt that achieves a 30% reduction in
new malaria infections. The value bt = 0.0047 achieves this percentage reduction.
ACT dramatically reduces the length of time a malaria patient is carrying infectious gametocytes in her blood, possibly down
to a mean infectious period of ten days, so we use γt =
1
10 days
−1 [16, 17, 28].
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Vaccine, like IPT, decreases the probability, bt, that a susceptible person becomes infected after a bite from an infectious
mosquito. Additionally, a vaccine could increase the recovery rate, γt, by exposing the immune system to parasite proteins or
decreasing the amount of parasites that reach the blood stage initially [10]. Olotu et al. report clinical trial results suggesting
that the four-year reduction in malaria episodes among vaccinated children is 23.5-24.3% [39]. As this should roughly corre-
spond to the percentage decrease in new malaria infections observed in the SIR model output, we calibrated the model by
solving the system of differential equations for a range of values for both bt and γt and selecting the combination that achieves a
roughly 24% reduction in new malaria infections. Choosing bt = 0.005 and γt =
1
5.5 days
−1 achieves this percentage reduction.
Possible actions that can be selected by the optimization model are to deploy no intervention, a single intervention, or
a combination of two interventions. Although it is possible to consider combining any pair of interventions, for modeling
simplicity, we only consider pairs of interventions whose coverage applies to the same segments of the population. Therefore,
because IPT and vaccines are assumed in our model to be distributed only to newborns and children under the age of four,
while LLIN, ACT and IRS are applied to the general population, the combinations we consider are IPT with vaccine, LLIN
with ACT, LLIN with IRS, or ACT with IRS.
When two interventions are used in combination, we assume the covered segment of the population receives both treat-
ments, and the uncovered segment receives neither. If the two interventions affect non-overlapping parameter sets, we assume
the combination intervention will affect the union of both sets of parameters in the same manner as the individual interven-
tions. However, some pairs of interventions act upon the same parameter. For example, in the case of LLIN combined with
IRS, the mosquito density, mt is affected by both interventions. Because we think it would be too optimistic to assume that
the effects of LLIN and IRS are additive, we make a more conservative assumption: we use the smallest values of at, mu and
mt offered by either LLIN or IRS. For the IPT with vaccine combination, bt, the transmission efficacy from infected mosquito
to susceptible, treated human, is reduced by both interventions via different mechanisms, and γt is increased by the vaccine.
We use the smaller of the two bt values under IPT and vaccine (that given by IPT, of bt = 0.0047) and the value of γt =
1
5.5
yielded by the vaccine.
Sensitivity Analysis Simulations
We examined the optimal sequence of five-year interventions through simulation of a fictitious nation. This nation consists
of 4,500 districts, each having a population of 10,000 (for a total population of 45 million, comparable to that of Kenya in
2014 [34]). We assume an annual budget of Bt = 33.75 million USD, which corresponds to 0.75 USD per person, per year.
(This is comparable to the budget for the President’s Malaria Initiative (PMI) in Kenya, which in 2013 was 34,256,770 USD
[40].)
Each of the 4,500 districts is characterized as belonging to one of nine geographic regions, which in turn are characterized by
one of three distribution regions and one of three climate regions. 500 districts belong to each of the nine possible combinations.
Distribution regions categorize districts by how inexpensively (relative to the baseline costs given earlier) interventions can
be distributed to the district. Rural and remote areas are likely to experience higher-than-baseline distribution costs due to
having worse road infrastructure and lower access to health centers. Centrally located urban areas are likely to experience
lower-than-baseline distribution costs. We assume districts categorized as having low distribution costs will have intervention
costs that are 20% lower than the baseline values given in Table 1. Districts categorized as having medium distribution costs
will incur the baseline intervention costs, and districts categorized as having high distribution costs will incur intervention
costs that are 20% more than the baseline costs given in Table 1.
The three climate regions, dry, moderate and wet, reflect the effect climatic characteristics such as temperature and
precipitation can have on mosquito population, and hence on malaria transmission dynamics. The moderate climate scenario
assumes the baseline mosquito density given above of mu = 20 mosquitoes per human The dry scenario assumes a mosquito
density of mu = 5 mosquitoes per human, and the wet scenario assumes a mosquito density of mu = 35 mosquitoes per
human. Each region is also characterized by its own initial population distribution amongst the S, I and R classes, which
was chosen to be the steady-state population distribution observed when the SIR model is run for a long period of time
from a variety of starting population distributions and assuming no intervention. For the moderate climate scenario, the
steady-state distribution used for the initial distribution was 15% susceptible, 15% infected, and 70% recovered. The dry
scenario used an initial steady-state distribution of 60% susceptible, 15% infected, and 25% recovered. The wet scenario
used an initial steady-state population distribution of 10% susceptible, 15% infected, and 75% recovered. (For computational
tractability, we use a population state resolution of five percentiles, and round the SIR population state to the nearest 5%,
while requiring that the percentages over all compartments sum to one.)
We also consider three efficacy scenarios to test the sensitivity of our model to the inherent uncertainty in our under-
standing of how effective the interventions are. The baseline efficacy scenario uses the baseline parameter estimates described
earlier and shown in Table 2. The pessimistic efficacy scenario assumes each parameter value for the treated class is 30%
“worse” than its baseline value, where by “worse”, we mean leading to greater malaria infections. The optimistic efficacy
scenario assumes each parameter value for the treated class is 30% “better” than its baseline value. In the case where making
a treatment parameter 30% worse than its baseline value ends up making it worse than the untreated baseline value, the value
is capped at the untreated baseline; in this way, we avoid a situation where the treated class might artificially experience
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more malaria cases than the untreated class.
Results and Discussion
We now present the results of running our model on the data described above. Because we use a simplified SIR model to
estimate the social costs of malaria as a function of interventions distributed, the purpose of this model is not to give exact
estimates of reductions in person-days of malaria infection, but relative results that can be used by the optimization model
to make choices between the various interventions. Our model provides qualitative insights about trends in the optimal inter-
ventions as certain parameters vary; these qualitative insights can then be used to offer high-level policy recommendations,
as we describe.
Table 3 and Figure 1 provide the sequence of interventions allocated in each of the nine geographic regions (low, medium
or high distribution costs, crossed with dry, moderate or wet climate) over a five-year horizon in the baseline efficacy case.
The total person-days of malaria infection was found to be 4.506 billion. In Figure 1, the first row of figures corresponds to
low distribution costs, the second row to medium distribution costs and the third row to high distribution costs. Likewise,
each column of figures corresponds to the same climate region (dry in red, moderate in yellow, wet in blue, from left to right).
The vertical axis on each graph lists in alphabetical order the interventions selected by the model at least once in at least
one geographic region and the associated coverage. The thickness of a path is proportional to the number of districts (out of
500) that were assigned that sequence of interventions. Table 3 gives the number of districts of each type that are assigned
a particular sequence of interventions, as well as the resulting (S, I,R) population state after each year.
We see that for dry climate regions, the sequence of interventions is the same regardless of distribution cost, namely,
ACT is distributed to 60% of the population in year 1, and then no subsequent interventions are distributed in years 2-5.
The reason for this is that distributing ACT at a coverage of 60% in year 1 eradicates (at least subject to rounding at our
resolution of 5%) malaria, driving the infected proportion of the population to zero. Per equations (16) and (17), the force
of infection is zero when the infected population is zero, and the disease cannot persist.
For the moderate climate regions, all districts are assigned ACT combined with LLIN at 60% coverage in the first year,
followed by ACT in combination with either LLIN or IRS at 60% coverage in subsequent years.
The sequence of interventions assigned in the wet regions at first glance appears more interesting. First we see that only
low distribution cost districts, along with only two medium distribution cost and one high distribution cost districts, receive
any intervention during the first year. 126 high distribution cost districts never receive any intervention in any of the five
years. This is likely due to the budget constraint forcing the model to prioritize eliminating malaria in the dry climate regions
during year one and leaving the harder-to-access wet regions largely untreated. In those wet districts receiving interventions,
the chosen interventions are primarily LLIN with ACT at 60% coverage. but as Table 3 shows, these interventions do little
to reduce the prevalence of malaria in the population. An apparent steady-state consists of 10% of the population in the
infected state even after several years of 60% coverage of LLIN with ACT. Thus, we can infer that combating malaria in the
wet regions is not possible with the interventions considered at coverage percentages up to 60%. As we show later, increasing
the maximum coverage to 80% is necessary for reducing malaria in wet regions.
Effect of Treatment Efficacy
We can examine the sequence of interventions allocated in the nine geographic regions under our optimistic and pessimistic
efficacy scenarios, in which the disease transmission parameter values for the treated class are adjusted up or down by 30%.
The optimistic case is depicted in Figure 2, with the full set of results given in Table 4, and the results for the pessimistic
case are given in Figure 3 and Table 5.
In the optimistic case, we see a reduction in person-days of malaria infection from 4.506 billion to 2.977 billion, or 34%.
In year one, the model focuses on eradicating (subject to rounding error) malaria in the dry and moderate climate regions by
allocating LLIN, ACT or the two in combination. All but seven of the 1500 wet climate districts receive no intervention in
year one. In subsequent years, the wet climate districts receive 60% coverage of LLIN with ACT, and ACT with IRS, with a
handful of wet climate districts receiving IPT or no intervention during years one and two. Although it appears that the dry
and moderate regions are also receiving interventions during years two through five, this is an artifact of the optimization
model: once the infectious population is driven to zero, there is no value in distributing further interventions; the model is
allocating interventions in these regions simply to use up the available budget. Moreover, the prevalence of malaria in the
wet regions appears to stabilize around 10% in year five. This is further indication that 60% coverage is not sufficient to
diminish malaria prevalence in the wet regions, even if we are optimistic about the interventions’ efficacy.
In the pessimistic case, we see an increase in person-days of malaria infection from 4.506 billion to 5.080 billion, or 13%.
In year one, resources are focused on rapidly reducing infections in the dry regions, by allocating 60% coverage of ACT;
remaining resources in year one are focused on the moderate climate regions. In subsequent years, the moderate regions
receive 60% coverage of ACT combined with either IRS or LLIN; the remaining budget is used to allocate a variety of
interventions in the wet regions. The takeaway message here is that to minimize person-days of malaria infection, the model
chooses to focus resources on the dry and moderate climate regions; any remaining budget is allocated to the wet regions.
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Effect of Coverage
If we assume that a maximum coverage of 80% (including both distribution and compliance) is attainable, we see that the
results change dramatically. Table 6 gives the sequence of interventions assuming a baseline efficacy and possible coverage
levels of 40%, 60% and 80% (rather than 20%, 40% and 60% used earlier), and using the same annual budget of 33.75 million
USD. We see that in all geographic regions, the infected population is driven to zero within two years, indicating that malaria
is effectively eradicated (at least subject to rounding at our resolution of 5%). Thus, achieving high coverage is crucial to
rapid eradication of malaria, even with the annual budget held constant. Although our intervention costs rise in proportion
to the treatment coverage, our fixed budget is able to achieve markedly lower person-days of malaria infection when 80%
coverage is achievable as opposed to only 60% (1.139 billion person days, as opposed to 4.506 billion person days,) although
some of this effect is likely due to rounding at resolution 5%. Thus, giving a smaller number of cities a higher coverage is
more effective than giving a larger number of cities a lower coverage. Moreover, it is only when 80% coverage is attainable
that we see a reduction of malaria prevalence in the wet climate regions.
Because the 80% coverage eradicates malaria so quickly in our model, the interpretation of the five-year model results
becomes less interesting. For this reason, we present the remainder of the results using the original coverage percentages of
20%, 40% and 60%, except where otherwise indicated.
Effect of Budget
Previous work by Dimitrov et al. suggested that increasing the budget would decrease malaria deaths roughly linearly up to a
critical budget value, after which there would be diminishing marginal benefit to additional budget expenditures [11]. Using
the baseline efficacy scenario, we solved the optimization problem sequentially for budgets ranging from 15 million USD to
155 million USD in increments of 10 million USD and plotted person-days of malaria infection against budget. As seen in
Figure 4, our results are consistent with Dimitrov et al. [11]. We find that the person-days of malaria infection decrease
linearly with an increase in budget until roughly 55 million USD, after which we observe diminishing marginal returns on
budget increases. Moreover, beyond a budget of 85 million USD, we observe no further reduction in person-days of malaria
infection. Also shown in Figure 4 is the plot of person-days of malaria infection in the baseline scenario when coverage up
to 80% is attainable. We see the same general shape to the graph, but with substantially lower values for the person-days of
malaria infection. Moreover, we see that even with a very large budget, 60% coverage cannot achieve the low prevalence of
malaria infection that 80% coverage can achieve with even a small budget.
Additionally, we can examine the qualitative change in the interventions chosen at different budget levels, as shown in
Figure 5. When the budget is 15 million USD, for instance, most districts receive no intervention in most years. Those
that do receive 60% coverage of ACT, either alone or in combination with either IRS or LLIN, or 40% coverage of IPT.
(Although not shown in Figure 5, the raw results from the simulation reveal that the dry regions receive interventions in
year one, which effectively eradicates malaria in those regions; most of the moderate climate regions receive interventions in
most years, with a cluster of high distribution cost districts receiving no intervention in any of the five years; and the wet
regions typically receive no intervention in most years.) When the budget is 85 million USD, Figure 5 shows that the number
of districts receiving no intervention in some year drops sharply. (A closer look at the raw results reveals that all regions
receive the maximum of 60% coverage of ACT in combination with IRS in all years, except for the dry regions, which receive
no intervention in years two through five after malaria has been effectively eradicated.)
Figure 6 shows the percentage of the total population that is in the infected class at the end of each of the five years, when
the annual budget is 15 million USD as compared to 85 million USD. A 15 million USD annual budget achieves a drop from
15% infected to around 8% infected in steady state. An 85 million USD annual budget achieves an initial drop to around
3% infected, which levels out to 5% infected in steady-state. (Note that this contrasts with the results shown previously in
Table 6 where if coverage of 80% is attainable, malaria is eradicated with only a 33.75 million USD budget.)
Role of Vaccine
We were surprised to observe that in all of our simulations across geographic regions, efficacy scenarios, maximum coverage,
and budgets, the vaccine was almost never chosen, either alone or in combination with IPT. Although the annual cost per
treated person is quite high (20.66 USD), the fact that it is distributed only to children under the age of four, comprising an
estimated 14.6% of the population, makes its district-wide cost on par with that of the other interventions. We can use our
model to understand under what conditions a malaria vaccine would be a cost-effective intervention by systematically lowering
its cost and increasing its efficacy. Specifically, we solved the optimization model on all combinations of bt = 0.001, 0.005, or
0.009, γt =
1
2 ,
1
5.5 , or
1
30 , and vaccine cost = 2, 5, 10, or 20.66 USD per person annually. Preliminary analysis of these results
showed little influence of either bt or γt on the number of times vaccine was selected; for most combinations of bt and γt,
vaccine will be frequently chosen if the cost is 2 or 5 USD and will rarely be chosen if the cost is 10 or 20.66 USD. Therefore,
we conclude that cost is a driving factor in the choice to select vaccines over other interventions. Figure 7 shows the number
of districts receiving vaccine, either alone or in combination with IPT, over the 5-year time horizon as a function of vaccine
cost, for the baseline efficacy scenario and using bt = 0.005, and γt =
1
5.5 . We see that when the vaccine cost is 2 USD per
person, it is selected quite often, but is selected far less frequently when the cost is 5 USD. Moreover, it is almost never
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selected at a cost of 10 or 20.66. Shown in the same figure is the person-days of malaria infection in those same instances.
We see that reducing the vaccine cost from 20.66 USD per person to 2 USD per person yields only a 1.5% reduction in
person-days of malaria infection, from 4.51 billion to 4.44 billion.
Role of Time Horizon
An important motivation underlying this work is the idea that distributing an intervention changes the malaria transmission
dynamics, which could affect future intervention choices. We can compare the interventions chosen in the first year of our
five-year time horizon to those chosen if we consider a time horizon of only a single year, as shown in Figure 8. As mentioned
above, in the first year of the five-year time horizon, resources are focused primarily on the dry and moderate climate regions
that receive either ACT alone at 60% coverage, or ACT in combination with LLIN at 60% coverage. Most of the medium-to-
high distribution cost districts in the wet regions receive no treatment during year one. Nearly 400 of the low distribution cost
districts in the wet regions get 20% coverage of LLIN with ACT, and the remaining 100 get 60% coverage of LLIN with ACT.
By contrast, if we solve the model using only a one-year time horizon, the solution changes. Dry regions (at all distribution
costs) again receive ACT alone at 60% coverage. Moderate climate regions having low or medium distribution costs receive
LLIN in combination with ACT at 60% coverage, as do 324 moderate climate regions having high distribution costs. However,
now 175 moderate climate districts having high distribution costs drop down to no intervention, and in return, all 500 wet
climate districts having low distribution costs receive LLIN with ACT at 60% coverage, which is substantially higher than
before. Thus, we see that incorporating a multi-year planning horizon that anticipates changes in the malaria transmission
as a result of the interventions distributed does indeed affect the optimal choice of intervention.
Role of Climate
There is a noticeable qualitative difference in the types of treatments distributed to the three climate regions considered.
Aggregating over all years and distribution cost categories for the baseline efficacy scenario, the first row of Figure 9 shows
the number of districts receiving each type of treatment, separated by climate region. We see that dry regions are adequately
served by ACT alone; moderate regions require ACT in combination with either LLIN or IRS; and wet regions get LLIN
alone, LLIN with ACT, ACT with IRS, and a handful of others (though as discussed earlier, this variety is likely the result
of the model using the available budget because no treatment at 60% coverage is very successful at reducing malaria in the
wet regions.)
If a lower-cost vaccine is available at 2 USD per person per year, the second row of Figure 9 shows that dry regions again
receive exclusively no intervention and ACT, and moderate regions again receive exclusively ACT in combination with either
IRS or LLIN. Now, however, in the wet regions, the number of years of “no intervention” drops significantly, from 2725 to
70, and we see that vaccine use, at either 40% or 60% coverage comprises nearly 50% of the pie chart.
The takeaway messages are that a single choice of intervention across all climate types is unlikely to be optimal, and that
the development of a low-cost malaria vaccine is likely to be of greatest use in regions with high mosquito densities; drier
areas are better served by ACT, alone or in combination with IRS and LLIN.
Conclusions
Because our model is very sensitive to the disease transmission parameter values used, it is best suited for qualitative
interpretations about relative benefits of certain interventions. For instance, while common sense might suggest we should
focus intervention resources on wet climate regions with high mosquito counts, the results of our model with a maximum
coverage of 60% suggest the opposite: to reduce person-days of malaria infection, it might be better to invest resources on
areas where interventions can dramatically reduce the prevalence of malaria, rather than expend resources on areas where
malaria is likely to persist, despite our best efforts. But if coverage closer to 80% is attainable, then malaria can be combatted
in wet climate regions. Likewise, our model can illustrate the sensitivity of the optimal policy to certain parameters. For
example, the optimal sequence of interventions varies by climate type (as represented by mosquito density), suggesting that
a one-size-fits-all approach to malaria eradication is not optimal. The sensitivity of the model to parameter assumptions also
signals that prior to using the model to guide policy in any given region, the choice of parameter values would first need to
be calibrated to match known malaria prevalence rates in the region.
Future refinements of the model could address acquired resistance to interventions, age-dependent immunity, spatial
effects of human or mosquito migration, and computational tractability. Drug resistance in malaria parasites and insecticide
resistance in mosquitoes are major challenges to control and eradication efforts [41, 42, 43]. Implementing resistance in this
model would require tracking decreased effectiveness of treatment after use in multiple consecutive years. This would increase
the computational challenge of solving the model, however, as the costs and benefits of choosing a particular intervention
in a given year would depend not only on the (S, I,R) population state but also on the sequence of interventions chosen in
prior years. Likewise, incorporating age-dependent immunity or spatial effects would also require an increase in the number
of population compartments in the (S, I,R) model. Already, we were limited by computational power in the resolution of the
population state we could consider. The bottleneck appears to be in the formulation of the integer linear programming model
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using AMPL. Although the data file is only 2MB at 5% resolution and 11MB at 2% resolution, loading the 5% resolution
data file into AMPL took approximately 15 minutes on a 32-core, 128 GB RAM parallel compute server located in the
Harvey Mudd College Mathematics Department, and attempting to load the data file for the 2% resolution case exceeded
the available 128 GB of RAM on the server. Once loaded, the 5% resolution model was subsequently solved by the CPLEX
solver within seconds. The technical staff at the NEOS server (an online server for optimization solvers on which we ran
earlier tests [44, 45, 46]) who are familiar with these modeling languages suggested using a more efficient modeling language
than AMPL for formulating the optimization model; we leave this as future work.
Given the growing interest in malaria eradication, the WHO Global Malaria Programme cites the need for operations
research studies to determine the best intervention strategies in areas where transmission dynamics are changing as malaria
is being eliminated. They also present a list of priority research questions that includes questions about safety, access, and
community involvement [2]. We have developed a flexible modeling framework that can guide such decisions. Our model
permits a multi-year planning horizon over areas characterized by disparate infrastructure and climate. Given inputs of the
per-person cost of each intervention and the effects each intervention has on malaria disease transmission parameters, the
model provides a sequence of interventions over a fixed time horizon that minimizes person-days of malaria infection subject
to an annual budget. Moreover, this model can be adapted to the treatment of other infectious diseases.
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Figure 1: Sequence of interventions over a five-year time horizon in the baseline efficacy scenario. The thickness of each line
is proportional to the number of districts assigned a given sequence. Intervention sequences assigned to only a single district
have been omitted from the figure (5 districts omitted in total). The total person-days of malaria infection in this scenario
is 4.506 billion.
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Figure 2: Sequence of interventions over a five-year time horizon in the optimistic efficacy scenario. The thickness of each
line is proportional to the number of districts assigned a given sequence. Intervention sequences assigned to only a single
district have been omitted from the figure (4 districts omitted in total). The total person-days of malaria infection in this
scenario is 2.977 billion.
Intervention Cost
None 0
LLIN 1.33
ACT 4.82
IPT 1.13
IRS 2.22
Vaccine 20.66
Table 1: Baseline cost for using interventions, per treated person for one year, in 2009 USD [29, 30, 31].
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Figure 3: Sequence of interventions over a five-year time horizon in the pessimistic efficacy scenario. The thickness of each
line is proportional to the number of districts assigned a given sequence. Intervention sequences assigned to only a single
district have been omitted from the figure (5 districts omitted in total). The total person-days of malaria infection in this
scenario is 5.080 billion.
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Figure 4: Total person-days of malaria infection over five-year horizon as a function of annual budget in the baseline efficacy
scenario. The solid line corresponds to a maximum attainable coverages of 60%. The dashed line corresponds to a maximum
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Figure 5: Interventions chosen (in district-years) under a 15 million USD annual budget as compared to an 85 million USD
annual budget, aggregated over all geographic regions and a five-year time horizon in the baseline efficacy scenario.
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compared to an 85 million USD annual budget (dashed line), aggregated over all geographic regions, in the baseline efficacy
scenario.
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Figure 7: Vaccine selection (in number of district-years) and person-days of malaria infection versus vaccine cost, over 5-year
time horizon, in the baseline efficacy scenario.
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Figure 8: First-year interventions chosen in a one-year time horizon versus a five-year time horizon, by climate region, in the
baseline efficacy scenario.
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Figure 9: Interventions chosen by climate region when vaccine cost is 20.66 USD per treated person versus a low-cost vaccine
having cost 2 USD per treated person, in the baseline efficacy scenario.
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Baseline Value Treatment Value
Symbol Description (untreated) LLIN IRS IPT ACT Vaccine
au, at Bites per mosquito per human per day 0.25 [33] au(1− β) [15]
bu, bt Transmission efficacy from infected 0.022 [33] 0.0047 0.005
mosquito to susceptible, untreated human
β Proportion of bites that would 0.8 [15]
occur while sleeping
c Transmission efficacy from 0.36 [33]
infected human to mosquito
δ Daily birth rate and death rate 4.7895 ∗ 10−5 [34]
assuming constant population
γu, γt Recovery rate in humans
1
180 [35]
1
10
1
5.5
mu, mt Mosquitoes per human 20 [13] mu(1− βχLLIN ) mu,IRS = mu(1− qχIRSu)
mt = mu(1− χIRSt) [38]
µ Mosquito mortality rate 0.095 [36, 35]
ω Duration of immunity without reinfection 274 days [37]
q Treatment coverage 0.2, 0.4 or 0.6
τ Incubation period in mosquito 10 days [36]
x Fraction of the population 0.146 [34]
0-4 years of age
χLLIN Probability of mosquito mortality 0.8 [14]
when exposed to a treated net
χIRSt Percent reduction in mosquito density 0.95 [38]
in a house treated with IRS
χIRSu Percent reduction in mosquito density 0.5 [38]
in an untreated house when all
nearby houses are treated with IRS
Table 2: Malaria transmission parameter values for the baseline, untreated case (corresponding to the subscript “u”) and treatment cases (corresponding to the
subscript “t”). In the Baseline Value column, an empty space means that the parameter does not apply to the baseline, untreated case. In the Treatment Value
columns, an empty space means that the parameter is unchanged by that particular intervention.
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Geographic Number of Initial Y1 Intervention Y2 Intervention Y3 Intervention Y4 Intervention Y5 Intervention
Region Districts Population State (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State)
(D, L) 500 (60, 15, 25) ACT 60% NONE NONE NONE NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, M) 500 (60, 15, 25) ACT 60% NONE NONE NONE NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, H) 500 (60, 15, 25) ACT 60% NONE NONE NONE NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, L) 500 (15, 15, 70) LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60% ACT IRS 60%
(65, 5, 30) (80, 5, 15) (85, 5, 10) (85, 5, 10) (85, 5, 10)
(M, M) 500 (15, 15, 70) LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60% LLIN ACT 60%
(65, 5, 30) (80, 5, 15) (85, 5, 10) (85, 5, 10) (75, 10, 15)
(M, H) 500 (15, 15, 70) LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60% LLIN ACT 60%
(65, 5, 30) (80, 5, 15) (85, 5, 10) (85, 5, 10) (75, 10, 15)
(W, L) 395 (10, 15, 75) LLIN ACT 20% ACT IRS 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(25, 10, 65) (65, 5, 30) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, L) 105 (10, 15, 75) LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, M) 276 (10, 15, 75) NONE LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, M) 136 (10, 15, 75) NONE LLIN ACT 20% ACT IRS 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (25, 10, 65) (65, 5, 30) (60, 10, 30) (60, 10, 30)
(W, M) 59 (10, 15, 75) NONE NONE LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30)
(W, M) 22 (10, 15, 75) NONE NONE NONE LLIN 20% LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (25, 10, 65) (55, 10, 35)
(W, M) 3 (10, 15, 75) NONE NONE IPT 40% LLIN 20% LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (25, 10, 65) (55, 10, 35)
(W, M) 2 (10, 15, 75) NONE IPT 40% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30)
(W, M) 1 (10, 15, 75) IPT 20% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, M) 1 (10, 15, 75) IPT 40% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, H) 371 (10, 15, 75) NONE NONE NONE NONE LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75) (60, 5, 35)
(W, H) 126 (10, 15, 75) NONE NONE NONE NONE NONE
(10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75)
(W, H) 1 (10, 15, 75) NONE NONE NONE NONE IPT 40%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75)
(W, H) 1 (10, 15, 75) NONE NONE IPT 40% NONE LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75) (60, 5, 35)
(W, H) 1 (10, 15, 75) IPT 40% IPT 40% IPT 40% IPT 20% LLIN ACT 60%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (10, 15, 75) (60, 5, 35)
Table 3: Optimal five-year (Y1 through Y5) sequences of interventions for the baseline efficacy scenario. Geographic Region refers to the climate region and distribution
cost pair, where the climate region is dry (D), moderate (M) or wet (W), and the distribution cost is low (L), medium (M) or high (H). Number of Districts refers to
the number of districts that were assigned a given trajectory. Initial Population State is the starting (S, I,R) percentages of the region; the End Population State for
a given year is the resulting (S, I,R) state after distributing the corresponding intervention. The total person-days of malaria infection in this scenario is 4.506 billion.
24
Geographic Number of Initial Y1 Intervention Y2 Intervention Y3 Intervention Y4 Intervention Y5 Intervention
Region Districts Population State (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State)
(D, L) 500 (60, 15, 25) LLIN ACT 60% ACT 60% ACT 20% ACT 60% NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, M) 500 (60, 15, 25) LLIN ACT 60% ACT 40% ACT 40% ACT 20% NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, H) 500 (60, 15, 25) ACT 60% ACT 60% ACT 40% ACT 60% ACT 40%
(85, 5, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, L) 500 (15, 15, 70) LLIN ACT 60% ACT IRS 60% NONE ACT 40% NONE
(65, 5, 30) (90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(M, M) 500 (15, 15, 70) LLIN ACT 60% ACT IRS 60% NONE ACT 20% ACT 40%
(65, 5, 30) (90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(M, H) 266 (15, 15, 70) LLIN ACT 60% ACT IRS 60% ACT 60% NONE ACT 40%
(65, 5, 30) (90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(M, H) 234 (15, 15, 70) LLIN 60% ACT IRS 60% ACT 60% NONE ACT 40%
(60, 5, 35) (90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(W, L) 497 (10, 15, 75) NONE LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15) (75, 10, 15)
(W, L) 3 (10, 15, 75) IPT 40% LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15) (75, 10, 15)
(W, M) 324 (10, 15, 75) NONE LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15) (75, 10, 15)
(W, M) 172 (10, 15, 75) NONE NONE LLIN ACT 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15)
(W, M) 2 (10, 15, 75) IPT 40% LLIN ACT 60% ACT IRS 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15) (75, 10, 15)
(W, M) 1 (10, 15, 75) NONE IPT 20% LLIN ACT 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15)
(W, M) 1 (10, 15, 75) NONE IPT 40% LLIN ACT 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15)
(W, H) 498 (10, 15, 75) NONE NONE LLIN ACT 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15)
(W, H) 1 (10, 15, 75) IPT 40% NONE LLIN ACT 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15)
(W, H) 1 (10, 15, 75) IPT 40% IPT 40% LLIN ACT 60% ACT IRS 60% ACT IRS 60%
(10, 15, 75) (10, 15, 75) (60, 5, 35) (80, 5, 15) (75, 10, 15)
Table 4: Optimal five-year (Y1 through Y5) sequences of interventions for the optimistic efficacy scenario. Geographic Region refers to the climate region and
distribution cost pair, where the climate region is dry (D), moderate (M) or wet (W), and the distribution cost is low (L), medium (M) or high (H). Number of
Districts refers to the number of districts that were assigned a given trajectory. Initial Population State is the starting (S, I,R) percentages of the region; the End
Population State for a given year is the resulting (S, I,R) state after distributing the corresponding intervention. The total person-days of malaria infection in this
scenario is 2.977 billion.
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Geographic Number of Initial Y1 Intervention Y2 Intervention Y3 Intervention Y4 Intervention Y5 Intervention
Region Districts Population State (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State)
(D, L) 500 (60, 15, 25) ACT 60% NONE NONE NONE NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, M) 500 (60, 15, 25) ACT 60% NONE NONE NONE NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, H) 500 (60, 15, 25) ACT 60% NONE NONE NONE NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, L) 494 (15, 15, 70) ACT 60% ACT IRS 60% ACT IRS 60% LLIN ACT 60% LLIN ACT 60%
(60, 5, 35) (80, 5, 15) (75, 10, 15) (70, 10, 20) (70, 10, 20)
(M, L) 6 (15, 15, 70) ACT 60% ACT IRS 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(60, 5, 35) (80, 5, 15) (75, 10, 15) (70, 10, 20) (70, 10, 20)
(M, M) 500 (15, 15, 70) LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(65, 5, 30) (75, 10, 15) (70, 10, 20) (70, 10, 20) (70, 10, 20)
(M, H) 500 (15, 15, 70) LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(65, 5, 30) (75, 10, 15) (70, 10, 20) (70, 10, 20) (70, 10, 20)
(W, L) 464 (10, 15, 75) NONE LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, L) 35 (10, 15, 75) LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, L) 1 (10, 15, 75) IPT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, M) 499 (10, 15, 75) NONE LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, M) 1 (10, 15, 75) IPT 40% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, H) 241 (10, 15, 75) NONE LLIN ACT 60% LLIN ACT 60% LLIN ACT 60% LLIN ACT 60%
(10, 15, 75) (60, 5, 35) (60, 10, 30) (60, 10, 30) (60, 10, 30)
(W, H) 140 (10, 15, 75) NONE NONE LLIN 20% NONE NONE
(10, 15, 75) (10, 15, 75) (20, 10, 70) (5, 15, 80) (10, 15, 75)
(W, H) 109 (10, 15, 75) NONE LLIN 20% NONE NONE NONE
(10, 15, 75) (20, 10, 70) (5, 15, 80) (10, 15, 75) (10, 15, 75)
(W, H) 3 (10, 15, 75) LLIN 20% NONE IPT 40% LLIN 20% LLIN ACT 60%
(20, 10, 70) (5, 15, 80) (10, 15, 75) (20, 10, 70) (55, 10, 35)
(W, H) 2 (10, 15, 75) NONE IPT 60% LLIN 20% NONE NONE
(10, 15, 75) (10, 15, 75) (20, 10, 70) (5, 15, 80) (10, 15, 75)
(W, H) 2 (10, 15, 75) NONE LLIN 20% NONE IPT 40% IPT 60%
(10, 15, 75) (20, 10, 70) (5, 15, 80) (10, 15, 75) (10, 15, 75)
(W, H) 1 (10, 15, 75) NONE NONE IPT 60% LLIN 20% IPT 20%
(10, 15, 75) (10, 15, 75) (10, 15, 75) (20, 10, 70) (10, 15, 75)
(W, H) 1 (10, 15, 75) NONE IPT 60% LLIN 20% NONE LLIN ACT 20%
(10, 15, 75) (10, 15, 75) (20, 10, 70) (5, 15, 80) (25, 10, 65)
(W, H) 1 (10, 15, 75) NONE LLIN 20% NONE IPT 40% NONE
(10, 15, 75) (20, 10, 70) (5, 15, 80) (10, 15, 75) (10, 15, 75)
Table 5: Optimal five-year (Y1 through Y5) sequences of interventions for the pessimistic efficacy scenario. Geographic Region refers to the climate region and
distribution cost pair, where the climate region is dry (D), moderate (M) or wet (W), and the distribution cost is low (L), medium (M) or high (H). Number of
Districts refers to the number of districts that were assigned a given trajectory. Initial Population State is the starting (S, I,R) percentages of the region; the End
Population State for a given year is the resulting (S, I,R) state after distributing the corresponding intervention. The total person-days of malaria infection in this
scenario is 5.080 billion.
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Geographic Number of Initial Y1 Intervention Y2 Intervention Y3 Intervention Y4 Intervention Y5 Intervention
Region Districts Population State (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State) (End Pop. State)
(D, L) 500 (60, 15, 25) ACT 80% ACT 60% NONE ACT 40% ACT 40%
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, M) 500 (60, 15, 25) ACT 80% ACT 80% ACT 80% ACT 40% ACT 60%
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(D, H) 500 (60, 15, 25) ACT 80% NONE ACT 80% ACT 40% NONE
(90, 0, 10) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, L) 500 (15, 15, 70) ACT 80% NONE ACT 80% ACT 80% NONE
(75, 0, 25) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, M) 500 (15, 15, 70) ACT 80% ACT 40% ACT 60% ACT 80% ACT 40%
(75, 0, 25) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, H) 404 (15, 15, 70) IPT 40% LLIN ACT 80% ACT 40% ACT 80% NONE
(20, 15, 65) (80, 0, 20) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(M, H) 92 (15, 15, 70) ACT 80% ACT 60% ACT 40% NONE NONE
(75, 0, 25) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(M, H) 3 (15, 15, 70) NONE LLIN ACT 80% ACT 40% ACT 80% NONE
(15, 20, 65) (80, 0, 20) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(W, L) 500 (10, 15, 75) LLIN ACT 80% NONE ACT 40% ACT 80% ACT 80%
(75, 0, 25) (95, 0, 5) (100, 0, 0) (100, 0, 0) (100, 0, 0)
(W, M) 500 (10, 15, 75) NONE ACT IRS 80% NONE ACT 60% ACT 60%
(10, 15, 75) (80, 0, 20) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(W, H) 354 (10, 15, 75) NONE ACT IRS 80% ACT 40% ACT 40% NONE
(10, 15, 75) (80, 0, 20) (95, 0, 5) (100, 0, 0) (100, 0, 0)
(W, H) 146 (10, 15, 75) NONE LLIN ACT 80% NONE ACT 40% NONE
(10, 15, 75) (75, 0, 25) (95, 0, 5) (100, 0, 0) (100, 0, 0)
Table 6: Optimal five-year (Y1 through Y5) sequences of interventions for the baseline efficacy scenario when the maximum coverage available for each intervention is
80%. Geographic Region refers to the climate region and distribution cost pair, where the climate region is dry (D), moderate (M) or wet (W), and the distribution
cost is low (L), medium (M) or high (H). Number of Districts refers to the number of districts that were assigned a given trajectory. Initial Population State is the
starting (S, I,R) percentages of the region; the End Population State for a given year is the resulting (S, I,R) state after distributing the corresponding intervention.
The total person-days of malaria infection in this scenario is 1.139 billion, and we see that in all geographic regions, malaria is eradicated over the five-year time
horizon.
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